Kólistímetat Natríum Xellia (Colistimethate Sodium)

Colistimethate sodium is a prodrug that is rapidly converted to colistin after administration. Colistin binds to the lipid A portion of lipopolysaccharides in the outer membrane of Gram‑negative bacteria, displacing calcium and magnesium ions. This destabilizes the membrane, increases its permeability, and causes leakage of intracellular contents, ultimately leading to bacterial cell death.

The dose of colistimethate sodium is individualized by the prescribing clinician based on the type and severity of infection, the patient’s renal function, body weight, and the route of administration (intravenous or intrathecal). Exact dosing regimens are not provided here and must be determined by a qualified healthcare professional.

Safety data for colistimethate sodium in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Colistimethate sodium is the sodium salt prodrug of colistin, the most widely used polymyxin. Compared with polymyxin B, colistin has a similar spectrum of activity but differs in pharmacokinetics and dosing requirements. Both agents share the risk of nephro‑ and neuro‑toxicity, but colistimethate sodium is typically administered intravenously, whereas polymyxin B is often given as a direct injection without conversion.

The product should be stored at 2‑8 °C, kept refrigerated, protected from light, and must not be frozen or shaken vigorously. Once reconstituted, it should be used promptly according to the manufacturer’s instructions and any remaining solution should be discarded if not used within the recommended time frame.

Kólistímetat Natríum is supplied as a sterile injectable solution for intravenous infusion or intrathecal injection. Administration is performed by a qualified healthcare professional, typically as a controlled infusion over a specified period. Dosage and infusion rate are determined by the prescriber based on infection severity, patient weight, and renal function.

The most serious adverse events include nephrotoxicity (acute kidney injury), neurotoxicity (neuromuscular blockade, seizures), severe allergic reactions such as anaphylaxis, and rare but life‑threatening skin reactions like Stevens‑Johnson syndrome. Early detection through regular laboratory monitoring and clinical assessment is essential.

Colistimethate sodium should be avoided in patients with known hypersensitivity to colistin or any component of the formulation. Caution is also advised for individuals with severe renal impairment, pre‑existing neuromuscular disorders, or those receiving concurrent nephrotoxic or neuromuscular‑blocking agents, unless the benefits clearly outweigh the risks.